AstraZeneca’s Strategic Move to Wall Street
AstraZeneca delists ADRs from Nasdaq for NYSE ordinary shares, attracting new U.S. investors.
AstraZeneca delists ADRs from Nasdaq for NYSE ordinary shares, attracting new U.S. investors.
Bullish shares set to open 62% above IPO, indicating strong investor confidence in digital assets.
Circle's market value exceeded $20 billion following its NYSE debut.